Shares of MedMira (TSX: V.MIR, Stock Forum) climbed more than 53% to ten cents Tuesday, as the Halifax-based developer and manufacturer of flow-through rapid diagnostics announced that the Centers for Disease Control and Prevention in the United States has selected its Multiplo HIV/Hepatitis C Rapid Test to be a part of a collaborative evaluation program.
This program of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention will see evaluations done in laboratories and in the field to determine the viability of rapid tests for use in screening and diagnosis of HIV and HCV in the United States, says the company.
“A number of rapid tests will be evaluated as part of the program however Multiplo HIV/HCV will be the only combination rapid flow-through test with the ability to deliver simultaneous results for HIV and HCV,” says the MedMira.
"We are very pleased that our Multiplo HIV/HCV test was selected for evaluation in this important CDC program. International evaluations and feedback from leading researchers have been very positive and we fully expect that our proven technology platform will continue to exceed expectations as part of this program," said Hermes Chan, CEO of MedMira.
On the company’s Bullboard, in a post entitled “Nice Surprise”, veterantrader said: “1 question though, did they SELL the product? There was no numbers.... They "provided" the rapid tests, but who payed for them?[sic]”
While Stockhouse member wesmile had the following questions:
(1) How long the program last?
(2) If OK by CDC what next?
(3) Why do big Pharmas not interested in MIR? Cost? Quality? Shelf Live?
Yes, this news is far better than draw-down while the share price is pointing south[sic]”
